Hospital of Skin and Venereal Diseases of Thessaloniki

Research site

Greece Delfon Str. 124, 546 43 Thessaloniki, Greece

1 trial recruiting
Epidermolysis bullosa
Adults and children

About Specializations

Hospital of Skin and Venereal Diseases of Thessaloniki in Thessaloniki, Greece specialises in clinical trials of conditions such as Epidermolysis bullosa, and other specialisations. This site conducts important research.

Epidermolysis bullosa

Main research areas of the site

Epidermolysis Bullosa Research

The medical center is at the forefront of research into Epidermolysis Bullosa, a rare genetic condition characterized by fragile skin that blisters easily. The center's research focuses on innovative therapeutic approaches to enhance wound healing and improve the quality of life for patients.

Wound Healing Enhancement
Symptom Management
Topical Treatment Development

Through the study of TCP-25 gel, the center aims to advance the understanding of effective treatments for Dystrophic Epidermolysis Bullosa (DEB) and Junctional Epidermolysis Bullosa (JEB), focusing on both efficacy and safety.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Delfon Str. 124546 43 ThessalonikiGreece

Open in maps ↗

Recruiting now: 1 trial
Conditions studied: 1

More sites in Thessaloniki Greece

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

1 clinical trial

Epidermolysis bullosa

Recruiting

Study on the Effects of TCP-25 Gel for Wound Healing in Patients with Epidermolysis Bullosa

Investigational

Study on the Effects of TCP-25 Gel for Wound Healing in Patients with Epidermolysis Bullosa

Investigational

Greece

Participants:0–17 years · 18–64 years · 65+ years
Substances:H-GLY-LYS-TYR-GLY-PHE-TYR-THR-HIS-VAL-PHE-ARG-LEU-LYS-LYS-TRP-ILE-GLN-LYS-VAL-ILE-ASP-GLN-PHE-GLY-GLU-OH
Sponsor:Xinnate AB

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites